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It is unclear whether psoriasis is a progressive di-
sease that requires early aggressive intervention. This 
population-based study identified patients with pso-
riasis and psoriatic arthritis (PsA). Survival analysis 
and Kaplan–Meier life table techniques were used. 
The study comprised 10,011 psoriasis patients (severe 
n = 4,618), and 1,269 patients also had PsA. Incidence 
of PsA increased with duration of cutaneous symptoms 
(p = 0.0001). Psoriasis diagnosed before age 20 or 
30 years, respectively, suggested a lower risk of PsA 
than psoriasis diagnosed after age 50 years, yet age 
at first cutaneous symptoms did not predict develop-
ment of PsA. No clear association with disease severity 
was found. PsA incidence appeared stable with longer 
duration of psoriasis, but further data are needed to 
firmly establish the relationship with age of psoriasis 
onset. 
Key words: psoriasis; psoriatic arthritis; disease duration; epi-
demiology.
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Cutaneous psoriasis (henceforth “psoriasis”) is a ma-nifestation of psoriatic disease, a chronic systemic 
inflammatory condition that affects 2–3% of Europeans, 
and up to 8% of populations in isolated parts of the 
northern Europe, in particular Scandinavia (Norway) 
(1). Plaque psoriasis (psoriasis vulgaris) is the most 
common form of psoriasis and is reported to account 
for almost 90% of all cases (2). The majority of patients 
(approximately 70–80%) have mild disease, i.e. pso-
riasis that can be managed with topical treatment alone 
(2, 3). Clinically, psoriasis is characterized by sharply 
demarcated hyperkeratotic and scaling plaques, which 
may be either localized or widespread, and a common 
extracutaneous manifestation includes psoriatic arthritis 
(PsA) (4). 
Psoriasis and PsA frequently co-exist (5, 6). Patients 
with PsA display increased inflammation of the periphe-
ral joints and skeleton, and may also have extra-articular 
manifestations, such as enthesitis and other musculoske-
letal manifestations (7, 8). While severity and prevalence 
of the different disease manifestations in PsA can differ 
greatly, the clinical picture may sometimes overlap with 
that of seronegative rheumatoid arthritis and ankylosing 
spondylitis, making the diagnosis difficult (8). It is well-
established that most patients with PsA develop psoriasis 
prior to onset of their arthritic symptoms, but the exact 
clinical relationship is insufficiently understood (9). For 
example, some studies have suggested a relationship 
between both severity and duration of psoriasis and the 
development of PsA, yet other reports have suggested 
that the incidence of PsA remains constant after the initial 
diagnosis of psoriasis (10–12). Nevertheless, on a popu-
lation level the incidence of PsA is steadily increasing 
across all age groups (13). To date, predictors for deve-
lopment of PsA have been identified, including severe 
psoriasis, nail involvement, low educational level, and 
uveitis, few of which are modifiable (14). The incidence 
of PsA is highest among patients in their fifth decade, 
the male-to-female ratio is 1:1, and the disease is most 
frequent among Caucasians (13, 15). Obesity is a reaso-
nably well-established risk factor for PsA among patients 
with psoriasis, yet while some studies have suggested 
that smoking, alcohol use, and the anatomical location 
of psoriasis may also be risk factors, the evidence for 
these are scarce and there is a need for additional studies 
to predict development of PsA in patients with psoriasis 
(16). We therefore examined the effect of duration of 
psoriasis on the risk of developing PsA in a nationwide 
cohort in Denmark.
METHODS
Data sources and study population
Study approval was obtained from the Danish Data Protection 
Agency (ref. 2007-58-0015, int. ref. GEH-2014-018, I-Suite 
02736). Danish register-based studies are exempted from ethics 
committee and institutional review board approvals. We conducted 
and reported the study in accordance with the recommendations 
of the Strengthening the Reporting of Observational Studies in 
Epidemiology (17). All records, including source codes for the 
present study, are kept at secured and encrypted servers held by 
Statistics Denmark. 
Individual-level information was linked from nationwide ad-
ministrative registers using a unique and unambiguous personal 
identification number that all Danish residents are assigned at birth 
or migration. The Civil Registration System (18) contains informa-
tion on sex, date of birth, and updated information on vital status 
and emigration, thus minimizing loss to follow-up. All inpatient 
and outpatient (ambulatory) hospital consultations are recorded 
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in the Danish National Patient Register (19) (DNPR) according to 
the International Classification of Diseases, 8th revision (ICD-8) 
prior to 1994, and according to the 10th revision (ICD-10) there-
after. Since 1994, all pharmacy-dispensed medication has been 
registered in the Danish Registry of Medicinal Products Statistics 
according to the Anatomical Therapeutic Chemical (ATC) clas-
sification (20), and drugs given directly from hospital clinics or 
during admission are recorded in the DNPR.
Among the entire population alive and resident in Denmark on 
31 December 2012, were identified all patients with a first-time 
hospital dermatologist diagnosis of psoriasis vulgaris (ICD-10 
L40.0, ICD-8 696.19) within the 18-year period up until 31 De-
cember 2012 (i.e. from 1 January 1995 until 31 December 2012). 
As patients may display cutaneous symptoms for some time prior 
to being diagnosed by a dermatologist, we also collected data 
regarding the date of their first claimed prescription for topical 
corticosteroids (ATC D07) or topical vitamin D analogues (ATC 
D05AX) as these therapies may have been prescribed for the 
condition before a dermatologist has formally diagnosed the 
patient. Among patients with cutaneous psoriasis, all patients 
with a rheumatologist diagnosis of PsA (ICD-10 M07.0-3 and 
M09.0, ICD-8 696.09) were identified. To ensure accuracy of 
diagnoses only those diagnoses made by dermatologists (pso-
riasis) and rheumatologists (PsA), respectively, were included. 
Patients were classified as having severe cutaneous psoriasis 
if they received systemic therapy for the condition (biological 
drugs (adalimumab, efalizumab, etanercept, infliximab, or us-
tekinumab), ciclosporin, psoralen plus ultraviolet A (PUVA), 
retinoids, or methotrexate) after the onset of psoriasis but before 
diagnosis of PsA.
Statistical analysis
For comparability with previous published findings, we used a 
similar statistical method to Christophers et al. (10). Thus, we 
dichotomized patients (psoriasis with PsA/psoriasis without PsA), 
and compared age, sex, duration of psoriasis, and age at time 
of diagnosis using Students t-test and Fischer’s exact test. The 
per-year incidence and prevalence of PsA was estimated using 
survival analysis, and the cumulative risk of PsA was calculated 
through use of Kaplan–Meier life tables; i.e. estimates were made 
based on the length at which psoriasis had been diagnosed at the 
time of PsA development. The per-year incidence of PsA was 
calculated based on the number of patients developing PsA of the 
total number of patients still at risk of incident PsA derived from 
the ltable function in Stata. Patients (n = 139) who had received a 
diagnosis of PsA before or on the same day as they were diagnosed 
with psoriasis were excluded. Two different sets of analyses were 
performed; first the date when patients were diagnosed with pso-
riasis by a dermatologist was used as the exposure, and thereafter 
the time of first cutaneous symptoms (defined as the time of first 
claimed prescription of topical corticosteroids or topical vitamin 
D analogues) was used as the exposure. In both sets of analyses, 
follow-up time was determined as the difference between diagnosis 
of psoriasis, or time of first cutaneous symptoms, respectively, 
and 31 December, 2012. A Poisson regression model was used to 
assess the incidence rate ratio (IRR) of PsA over time following 
prescription of first cutaneous symptoms. In addition, analyses 
were performed to assess the potential impact of age at psoriasis 
diagnosis on the risk of developing PsA. Therefore, individuals 
diagnosed with psoriasis before the age of 30 years,; and those 
diagnosed after the age of 50 years were compared using Fischer’s 
exact test, and a logistic regression model was applied to control 
for sex and time since diagnosis of psoriasis. In these analyses, 
individuals diagnosed with psoriasis between the ages of 30 and 
50 years were excluded. Since using the age of 30 years as the 
cut-off was an arbitrary choice, similar analyses were performed, 
in which psoriasis diagnosed before the age of 20 years was used 
as the cut-off instead. Finally, these analyses were then repeated 
using logistic regression with data from the entire study group and 
treating age as a continuous variable. Analyses were performed 
using SAS v9.4 (SAS Institute Inc., Cary, NC, USA) and STATA 
v13.0 (StataCorp, College Station, TX, USA). 
RESULTS
A total of 10,011 patients with psoriasis were included in 
these analyses (4,618 with severe disease). Of the total, 
1,269 (12.7%) were diagnosed with both psoriasis and 
PsA (Table I). All patients (100%) had received topical 
treatment. Patients with psoriasis with and without PsA 
were of similar age, had a longer duration of psoriasis, 
but a comparable male-to-female ratio as those with 
psoriasis without PsA. 
Table I. Demographics and characteristics of patients with psoriasis with or without psoriatic arthritis (PsA)
Characteristics
Psoriasis
(n = 8,742)
Psoriasis 
and PsA
(n = 1,269) p-value
Mild 
psoriasis
(n = 4,791)
Mild psoriasis 
and PsA
(n = 592) p-value
Severe 
psoriasis
(n = 3,951)
Severe psoriasis 
and PsA
(n = 667) p-value
Age, years, mean ± SD 51.8 ± 18.1 52.5 ± 14.5 0.182 50.9 ± 19.2 52.0 ± 14.7 0.200 52.8 ± 16.9 52.9 ± 14.2 0.845
Sex, n (%) 0.880 0.688 0.267
 Women 4,265 (48.8) 622 (49.0) 2,494 (52.1) 303 (51.2) 1,771 (44.8) 319 (47.1)
 Men 4,477 (51.2) 647 (51.0) 2,297 (47.9) 289 (48.8) 2,180 (55.2) 358 (52.9)
Age at psoriasis onset, years, mean ± SD
 Dermatologists diagnosis 44.0 ± 18.3 44.8 ± 14.8 0.138 42.9 ± 19.4 44.8 ± 14.8 0.018 45.4 ± 16.7 44.8 ± 14.8 0.380
 Cutaneous symptoms 37.7 ± 17.7 37.4 ± 14.4 0.522 37.2 ± 18.6 37.2 ± 14.4 0.993 38.4 ± 16.5 37.6 ± 13.9 0.235
Psoriasis duration at baseline, years, mean ± SD
 Dermatologists diagnosis 7.7 ± 5.1 7.6 ± 4.8 0.568 8.0 ± 5.2 7.1 ± 4.8 < 0.001 7.4 ± 4.9 8.1 ± 4.7 < 0.001
 Cutaneous symptoms 14.0 ± 4.3 15.1 ± 3.5 < 0.001 13.7 ± 4.5 14.8 ± 3.7 < 0.001 14.4 ± 4.1 15.3 ± 3.2 < 0.001
Psoriasis duration at PsA onset, years, mean ± SD
  Dermatologists diagnosis NA 3.5 ± 3.7 NA 2.8 ± 3.4 NA 4.0 ± 3.8
  Cutaneous symptoms NA 8.5 ± 4.6 NA 7.3 ± 4.6 NA 9.5 ± 4.2
Alcohol abuse, n (%) 899 (10.3) 138 (10.9) 0.519 500 (10.4) 65 (11.0) 0.684 399 (10.1) 73 (10.8) 0.587
Smoking, n (%) 1,346 (15.4) 201 (15.8) 0.684 684 (14.3) 82 (13.9) 0.78 662 (16.8) 119 (17.6) 0.598
Hypertension, n (%) 1,781 (20.4) 287 (22.6) 0.065 932 (19.5) 125 (21.1) 0.337 849 (21.5) 162 (23.9) 0.156
Diabetes, n (%) 816 (9.3) 150 (11.8) 0.005 408 (8.5) 56 (9.5) 0.44 408 (10.3) 94 (13.9) 0.006
Cholesterol-lowering drug use, n (%) 1,520 (17.4) 232 (18.3) 0.433 765 (16.0) 93 (15.7) 0.871 755 (19.1) 139 (20.5) 0.386
Charlson comorbidity index, mean ± SD 0.3 ± 1.0 0.2 ± 1.0 0.228 0.3 ± 1.0 0.4 ± 1.0 0.266 0.3 ± 1.0 0.4 ± 0.9 0.606
SD: standard deviation.; NA: not applicable.
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Fig. 1 shows the incidence and prevalence of PsA 
associated with time since psoriasis diagnosis (p for 
trend = 0.6593) and since first cutaneous symptoms (p 
for trend = 0.0001), respectively. Stratified analyses 
(time since diagnosis) by disease severity showed no 
significant trend (p = 0.4936) for those with mild disease, 
but a significant trend for those with severe psoriasis 
(p = 0.0002). Moreover, analyses of time since the first 
cutaneous symptoms showed that the trend was signifi-
cant across severities (both p < 0.0001). 
Comparing patients with early onset of cutaneous pso-
riasis symptoms (before age 30 years, total: 3,471, mild: 
1,932, severe: 1,539) with those with late onset (after age 
50 years, n = 2,676; mild: 1,452, severe: 1,224) yielded a 
significantly higher PsA occurrence in early onset com-
pared with late onset of any psoriasis (11.5% vs. 9.5%; 
p = 0.012), mild psoriasis (9.4% vs. 7.9%; p = 0.078) and 
severe psoriasis (14.1% vs. 11.2%; p = 0.030), respec-
tively. Duration of cutaneous symptoms was slightly 
longer for those with early- vs. late-onset psoriasis (mean 
length of time with cutaneous symptoms: 13.9 ± 4.1 years 
vs. 13.6 ± 4.7 years; p = 0.0011). No significant difference 
in duration of cutaneous symptoms was found in early 
vs. late psoriasis in mild cases (mean 13.5 ± 4.4 years vs. 
13.3 ± 4.8 years; p = 0.1561), but a significant difference 
was observed for severe disease (mean 14.5 ± 3.8 years 
vs. 13.9 ± 4.5 years; p = 0.0003). PsA risk was compared 
in those with early- vs. late-onset psoriasis (Table II), 
showing that early onset of psoriasis (age < 30 years) was 
insignificantly associated with a lower risk of PsA deve-
lopment when compared with those with late (age > 50 
years) psoriasis onset (odds ratio (OR) 0.84; 95% con-
fidence interval (CI) 0.71–1.00; p < 0.051). Conversely, 
when time of first cutaneous symptoms was used, rather 
than time of psoriasis diagnosis a slightly higher risk was 
shown (p = 0.018). No clear signal was observed with 
either diagnosis or cutaneous symptoms across severities 
(Table II). Psoriasis diagnosed before the age of 20 years 
(total: 1,011, mild: 704, severe: 307), was associated with 
a lower risk of PsA development (early- vs. late-onset 
psoriasis, OR 0.52; 95% CI 0.39–0.69, p < 0.001). Nota-
bly however, presence of cutaneous symptoms before the 
age of 20 years (total: 1,743, mild: 1,059, severe: 684) 
was not significantly associated with increased risk of 
PsA (OR 1.03; 95% CI 0.84–1.27, p = 0.777). PsA risk 
Table II. Logistic regression models assessing early (< 20a or < 30b 
years) vs. late (> 50 years) onset psoriasis and risk of psoriatic 
arthritis (PsA)
Odds ratio 95% CI p-value
Diagnosis
Earlya vs. late-onset psoriasis 0.52 0.39–0.69 < 0.001
  Mild psoriasis 0.38 0.25–0.57 < 0.001
  Severe psoriasis 0.84 0.56–1.26 0.403
Earlyb vs. late-onset psoriasis 0.84 0.71–1.00 0.051
  Mild psoriasis 0.69 0.55–0.88 0.003
  Severe psoriasis 1.09 0.86–1.38 0.478
Cutaneous symptoms
Earlya vs. late-onset psoriasis 1.03 0.84–1.27 0.777
  Mild psoriasis 1.05 0.78–1.41 0.729
  Severe psoriasis 1.08 0.80–1.45 0.626
Earlyb vs. late-onset psoriasis 1.22 1.03–1.45 0.018
  Mild psoriasis 1.19 0.94–1.53 0.154
  Severe psoriasis 1.28 1.02–1.61 0.035
Estimates are adjusted for sex and duration of cutaneous symptoms. Late-onset 
psoriasis serves as the reference group. CI: confidence interval.
Fig. 1. Incidence and cumulative prevalence of psoriatic arthritis (PsA) over time in the population of psoriasis patients. (A) Percentage 
of patients with psoriasis who develop PsA per annum (years since psoriasis diagnosis). (B) Percentage of patients with psoriasis who develop PsA per 
annum (years since first cutaneous symptoms). (C) Cumulative percentage of patients with psoriasis who develop PsA (years since psoriasis diagnosis). 
(D) Cumulative percentage of patients with psoriasis who develop PsA (years since first cutaneous symptoms). Blue: any psoriasis; red: mild psoriasis; 
green: severe psoriasis.
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was not significantly different among those receiving 
systemic treatment (severe psoriasis) or among patients 
receiving topical therapy (Table II). When age at pso-
riasis diagnosis was treated as a continuous variable this 
did not predict the risk PsA (OR 1.00 for an additional 
year of age; 95% CI 1.00–1.00; p = 0.7613). Including 
patients diagnosed between the age of 20–50 years into 
the analysis did also not predict development of PsA (OR 
1.00 for an additional year of age; 95% CI 1.00–1.00; 
p = 0.1597). Using a Poisson regression model, the IRR 
of PsA over time following onset of cutaneous symptoms 
was 1.03 (95% CI 1.02–1.05, p < 0.0001).
DISCUSSION
In this nationwide study of dermatologist-diagnosed 
patients with psoriasis, the incidence of PsA appeared 
to be stable with longer duration of psoriasis. Moreover, 
we observed no clear signal between age at psoriasis 
diagnosis or onset of cutaneous symptoms, and future 
development of PsA. Duration of cutaneous symptoms 
was significantly associated with risk of PsA in a Poisson 
regression model.
To date, very few studies have examined the as-
sociation between psoriasis duration and risk of PsA. 
Christophers et al. (10) examined 1,560 patients with 
psoriasis, including 126 with PsA, seen in dermatology 
clinics across the UK, Italy, France, Spain and Germany, 
respectively. While the study found a growing prevalence 
of PsA of up to 20.5% with longer psoriasis disease 
duration, the authors reported that the incidence of PsA 
remained constant in any given year after the initial 
diagnosis of psoriasis. However, as indicated in their 
study discussion, the PsA diagnosis was made by der-
matologists rather than by rheumatologists, which could 
have led to diagnostic uncertainty, and the study may 
also have suffered from bias in selection of study cases.
Speculative, prolonged exposure to systemic low-
grade psoriatic inflammation could, at least in theory, 
affect PsA incidence among those with longer duration 
of psoriasis. Along this line, several observational studies 
have reported beneficial effects of anti-inflammatory 
agents, such as tumour necrosis factor (TNF) inhibi-
tors, on cardiovascular comorbidities in patients with 
psoriasis (21) and other inflammatory diseases, such as 
rheumatoid arthritis (22), their impact on the effect of 
disease duration remains unclear. Since TNF inhibitors 
have proven efficacy, not only in psoriasis, but also in 
PsA, early and aggressive treatment of psoriasis symp-
toms with anti-TNF and other biological agents could 
potentially affect the development of overt symptoms 
of PsA. However, as with cardiovascular comorbidities 
where recent experimental studies have failed to replicate 
observational findings (23), our hypothesis remains to be 
tested in a clinical setting. It is currently being discus-
sed whether early- and late-onset psoriasis are geneti-
cally distinct entities. Interestingly, the HLA-Cw*06 and 
HLA-DRB1*07 genes are associated with increased risk 
of PsA, especially in early-onset psoriasis (24). 
Certain limitations apply to the interpretation of the 
present findings, the most important being that observa-
tional studies inherently cannot establish causality. We 
used systemic treatment as a measure of severe psoria-
sis. This method has previously been validated and is 
widely accepted in epidemiological psoriasis research 
(25). Nevertheless, we lacked important data on clinical 
measures of psoriasis severity, such as the Psoriasis Area 
and Severity Index, or the degree of affected body surface 
area, and our results should be interpreted accordingly. 
While the association between duration of cutaneous 
symptoms and risk of PsA seen in the Poisson regression 
model is intriguing, this finding warrants replication in 
other cohorts, and we emphasize that onset of psoriasis 
based on observational data is only an estimation. We 
found a lower risk among patients diagnosed < 20 and 
< 30 years, respectively, compared with those with late-
onset (> 50 years) psoriasis, yet the results for onset of 
cutaneous symptoms were conflicting in this regard, 
since the risk tended to be higher among those with 
early onset of cutaneous symptoms. Thus, based on 
the present findings we are unable to establish any firm 
conclusions regarding risk of PsA associated with age 
of psoriasis onset. We limited PsA diagnoses to those 
made by rheumatologists, in order to ensure diagnostic 
accuracy; however, this may have led to a selection of 
patients with more severe disease. Important strengths 
of our study include the completeness and accuracy of 
the Danish nationwide registries with minimal loss to 
follow-up, the ascertainment of diagnoses by dermato-
logists and rheumatologist, respectively, and the high 
number of included patients. 
In conclusion, our data suggested that the PsA inci-
dence remains stable with longer duration of psoriasis. 
Conflicting data were found with regards to PsA risk 
associated with age of psoriasis onset. There remains a 
lack of data in this area, and further studies are warranted 
to assess the effect of age of psoriasis onset on the risk 
of future development of PsA. 
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